share_log

亚宝药业(600351.SH):地氯雷他定口服溶液取得药品注册证书

Yabao Pharmaceutical Group (600351.SH) has obtained the pharmaceutical registration certificate for Desloratadine oral solution.

Gelonghui Finance ·  Aug 6 03:38

Yabao Pharmaceutical Group (600351.SH) announced that its wholly-owned subsidiary, Yabao Pharmaceutical Sichuan Co., Ltd., has received the Drug Registration Certificate issued by the National Medical Products Administration for Desloratadine Oral Solution. Desloratadine is a selective peripheral H1 antagonist and a tricyclic antihistamine. It is also an antagonist of all subtypes of muscarinic acetylcholine receptors. It is used for the relief of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis symptoms, as well as pruritus and symptomatic treatment of urticaria associated with chronic idiopathic urticaria.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment